加兰他胺对多克索鲁比诱导的神经毒性的保护作用
Rawan S Alsikhan1,2, Maha A Aldubayan1, Ibtesam S Almami3
1Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Brain sciences
|June 28, 2023
概括
氨酸 (GAL) 通过减少神经炎症,可以预防多克索鲁比 (DOX) 诱导的认知障碍. 这项研究表明,GAL可以改善记忆力,减少大脑中的炎症标志物,为化疗相关的认知缺陷提供潜在的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 多克索鲁比 (DOX) 是一种已知会导致认知障碍的化疗剂,通常被称为"化学大脑".
- 胆固醇系统与DOX诱导的神经毒性有关,但针对该系统的保护策略尚未得到充分探索.
- 胺 (GAL) 是一种乙胆酶抑制剂,具有已知的神经保护性质.
研究的目的:
- 调查多克索鲁比 (DOX) 诱导的认知缺陷背后的机制.
- 为了评估Galantamine (GAL) 在缓解DOX诱导的化学大脑中的潜在神经保护作用.
- 在DOX治疗的背景下,评估GAL对神经炎症标志物的影响.
主要方法:
- 雌性Wistar大鼠被分配到对照组,DOX,GAL或DOX + GAL组.
- DOX是通过腹膜内注射的,而GAL是每天口服15天.
- 行为测试 (Y-迷宫,NOR,EPM) 评估记忆功能,随后对脑组织中的炎症标志物 (TNF-α,IL-1β,IL-6) 和RT-qPCR进行生物化学分析.
主要成果:
- 在行为测试中,DOX治疗导致体重减少,生存率和显著的记忆障碍.
- 同时的 GAL 治疗 (DOX + GAL) 缓解了这些影响,改善了记忆功能和生存率.
- 生物化学分析显示,GAL逆转了DOX诱导的大脑炎症标志物 (IL-1β,IL-6,TNF-α) 和它们的mRNA表达的增加.
结论:
- 氨酸 (GAL) 对多克索鲁比 (DOX) 诱导的认知障碍表现出显著的神经保护作用.
- 通过减少大脑中的关键炎症标志物,GAL可以减轻DOX诱导的神经炎症.
- 这些发现表明,GAL是一种潜在的治疗药物,可以对抗化疗相关的认知功能障碍.
相关概念视频
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
353
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
353
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
208
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
208
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:22Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
01:24Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303